2015
Community Health Worker Perspectives on Barriers to HIV+ Patients' Initiation of and Retention in Antiretroviral Therapy in Rural South Africa
Loeliger K, Niccolai L, Mntungwa N, Moll A, Friedland G, Shenoi S. Community Health Worker Perspectives on Barriers to HIV+ Patients' Initiation of and Retention in Antiretroviral Therapy in Rural South Africa. Open Forum Infectious Diseases 2015, 2: 405. DOI: 10.1093/ofid/ofv133.281.Peer-Reviewed Original ResearchLymphadenopathy/lymphadenitis
Shenoi S, Friedland G. Lymphadenopathy/lymphadenitis. 2015, 184-191. DOI: 10.1017/cbo9781139855952.033.Peer-Reviewed Original Research
2013
The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadoneAdverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosisPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2010
HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial
Mosam A, Shaik F, Uldrick T, Esterhuizen T, Friedland G, Scadden D, Aboobaker J, Coovadia H. HAART and response to therapy improve quality of life (QOL) of African patients with advanced HIV-associated Kaposi’s sarcoma (HIV-KS): a prospective analysis of QOL in the KAART trial. Infectious Agents And Cancer 2010, 5: a30. PMCID: PMC3002689, DOI: 10.1186/1750-9378-5-s1-a30.Peer-Reviewed Original Research
2009
Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770
Uldrick T, Mosam A, Shaik F, Friedland G, Skadden D, Jordaan J, Aboobaker J, Coovadia H. Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770. Infectious Agents And Cancer 2009, 4: p41. PMCID: PMC4261824, DOI: 10.1186/1750-9378-4-s2-p41.Peer-Reviewed Original ResearchAverting epidemics of extensively drug-resistant tuberculosis
Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, Moll A, Moodley P, Sturm AW, Galvani AP. Averting epidemics of extensively drug-resistant tuberculosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 7672-7677. PMID: 19365076, PMCID: PMC2678614, DOI: 10.1073/pnas.0812472106.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisXDR-TBXDR-TB epidemicDrug susceptibility testingCommunity-based EpidemicsCommunity-based programsEffective reproductive numberTertiary hospitalTB epidemicDisease presentationPublic health conditionsCase findingTransmission clustersDiagnostic approachHealth conditionsSouth African communityOngoing transmissionTransmission dynamicsTherapyTuberculosisEpidemicReproductive numberTBKwaZulu-Natal ProvinceHospital
2008
Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial
Burman W, Grund B, Neuhaus J, Douglas J, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C. Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2008, 49: 142-150. PMID: 18769356, PMCID: PMC2749067, DOI: 10.1097/qai.0b013e318183a9ad.Peer-Reviewed Original ResearchConceptsHIV transmission riskHigh-risk behaviorsEpisodic antiretroviral therapyAntiretroviral therapyTransmission riskContinuous antiretroviral therapyHIV RNA levelsAntiretroviral Therapy studyProportion of participantsTherapy armContinuous therapyControlled TrialsRandomized armHIV transmissionMean ageNeedle sharingPatientsTherapyTherapy studiesStrategy of managementRNA levelsSexual activityRiskBaselineLaboratory testingMild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals
Mannheimer SB, Wold N, Gardner EM, Telzak EE, Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G, AIDS T. Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals. Clinical Infectious Diseases 2008, 46: 941-945. PMID: 18279044, DOI: 10.1086/528859.Peer-Reviewed Original ResearchPharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuse
2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2006
Development and Assessment of an Innovative Culturally Sensitive Educational Videotape to Improve Adherence to Highly Active Antiretroviral Therapy in Soweto, South Africa
Wong IY, Lawrence NV, Struthers H, McIntyre J, Friedland GH. Development and Assessment of an Innovative Culturally Sensitive Educational Videotape to Improve Adherence to Highly Active Antiretroviral Therapy in Soweto, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s142-s148. PMID: 17133198, DOI: 10.1097/01.qai.0000248345.02760.03.Peer-Reviewed Original ResearchConceptsEducational videotapeARV-naive patientsMedication-taking experiencesHIV-positive patientsActive antiretroviral therapyPatient education programHealth care providersAntiretroviral therapyARV therapyMedication therapyMedication takingAdequate adherenceAdherence counsellorsPatient understandingCare providersSide effectsPotential efficacyPatientsTherapyAdherenceFurther studiesIndividual adherencePreliminary findingsFocus groupsMeasurable benefitsPharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedications
2005
Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa
Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, Friedland GH, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS 2005, 19: 441-443. PMID: 15750399, DOI: 10.1097/01.aids.0000161775.36652.85.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyKaposi's sarcomaCopies/Generic antiretroviral therapyUndetectable viral loadActive antiretroviral therapyGeneric antiretroviral drugsAntiretroviral efficacyViral loadAntiretroviral drugsLog10 declineClinical experienceSarcomaTherapySaharan AfricaSub-Saharan AfricaHIVPatientsAIDSBaseline
2004
Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries
Friedland G, Karim S, Karim Q, Lalloo U, Jack C, Gandhi N, Sadr W. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases 2004, 38: s421-s428. PMID: 15156433, DOI: 10.1086/421407.Peer-Reviewed Original ResearchConceptsHIV infectionAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionTherapy programHIV/AIDS careObserved therapy programActive antiretroviral therapyImmunodeficiency virus infectionImmune deficiency syndromeBurden of diseaseResource-limited countriesResource limited countriesHIV/AIDSHIV diseaseTuberculosis careDisease burdenDeficiency syndromeAIDS careVirus infectionTuberculosisInfectionMajor causeDiseaseTherapyInadequate access
2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount
2001
Trust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice F, Mostashari F, Friedland G. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47-58. DOI: 10.1097/00126334-200109010-00008.Peer-Reviewed Original ResearchInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agentsTrust and the Acceptance of and Adherence to Antiretroviral Therapy.
Altice FL, Mostashari F, Friedland GH. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47. PMID: 11579277, DOI: 10.1097/00042560-200109010-00008.Peer-Reviewed Original ResearchConceptsInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agents